EFFECT OF FAMOTIDINE ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTOR Xa INHIBITOR, IN HEALTHY SUBJECTS.

被引：0
|
作者：
Uprett, Vijay V. [1 ]
Song, Yan [1 ]
Wang, Jessie [1 ]
Farmer, Mathew [1 ]
Pursley, Janica M. [1 ]
Li, Tong [1 ]
Frost, Charles E. [1 ]
LaCreta, Frank P. [1 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2009年 / 49卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
117
引用
收藏
页码：1117 / 1117
页数：1
相关论文
共 50 条
  • [41] Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
    Dagmar Kubitza
    Michael Becka
    Georg Wensing
    Barbara Voith
    Michael Zuehlsdorf
    European Journal of Clinical Pharmacology, 2005, 61 : 873 - 880
  • [42] Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects
    Jiang, Ji
    Hu, Yufang
    Zhang, Jianyan
    Yang, Jueling
    Mueck, Wolfgang
    Kubitza, Dagmar
    Bauer, Richard J.
    Meng, Ling
    Hu, Pei
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (01) : 234 - 241
  • [43] Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
    Kan He
    Joseph M. Luettgen
    Donglu Zhang
    Bing He
    James E. Grace
    Baomin Xin
    Donald J. P. Pinto
    Pancras C. Wong
    Robert M. Knabb
    Patrick Y. S. Lam
    Ruth R. Wexler
    Scott J. Grossman
    European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36 : 129 - 139
  • [44] Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor
    Richard C. Becker
    Hongqiu Yang
    Yuchen Barrett
    Puneet Mohan
    Jessie Wang
    Lars Wallentin
    John H. Alexander
    Journal of Thrombosis and Thrombolysis, 2011, 32 : 183 - 187
  • [45] Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
    He, Kan
    Luettgen, Joseph M.
    Zhang, Donglu
    He, Bing
    Grace, James E., Jr.
    Xin, Baomin
    Pinto, Donald J. P.
    Wong, Pancras C.
    Knabb, Robert M.
    Lam, Patrick Y. S.
    Wexler, Ruth R.
    Grossman, Scott J.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2011, 36 (03) : 129 - 139
  • [46] Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects
    Paccaly, A
    Frick, A
    Ozoux, ML
    Chu, V
    Rosenburg, R
    Hinder, M
    Shukla, U
    Jensen, BK
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01): : 45 - 51
  • [47] Apixaban, an oral, direct and highly selective factor Xa inhibitor:: in vitro, antithrombotic and antihemostatic studies
    Wong, P. C.
    Crain, E. J.
    Xin, B.
    Wexler, R. R.
    Lam, P. Y. S.
    Pinto, D. J.
    Luettgen, J. M.
    Knabb, R. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (05) : 820 - 829
  • [48] Single-dose pharmacokinetics of the direct renin inhibitor aliskiren in healthy Chinese subjects.
    Bartlett, M.
    Vaidyanathan, S.
    Karan, R. S.
    Hu, P.
    Howard, D.
    Yeh, C. M.
    Dieterich, H. A.
    Al-Fayoumi, S.
    Jarugula, V.
    Doles, W. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S62 - S62
  • [49] Multiple-dose pharmacokinetics of the direct renin inhibitor aliskiren in healthy Chinese subjects.
    Bartlett, M.
    Vaidyanathan, S.
    Karan, R. S.
    Hu, P.
    Howard, D.
    Yeh, C. M.
    Dieterich, H. A.
    Al-Fayoumi, S.
    Jarugula, V.
    Dole, W. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S61 - S62
  • [50] PHARMACODYNAMIC INTERACTION BETWEEN TAK-442, AN ORAL DIRECT FACTOR XA INHIBITOR, AND PRASUGREL IN HEALTHY SUBJECTS
    Wood, Nolan
    Stringer, Fran
    Wu, Ruishan
    Kawamura, Masaki
    Spaeder, Jeff
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E1504 - E1504
12345